Skip to main content
Premium Trial:

Request an Annual Quote

Becton Dickinson, BioGX Get FDA Emergency Use Authorization for Rapid SARS-CoV-2 Test

NEW YORK – Becton Dickinson and BioGX announced Friday that they received Emergency Use Authorization from the US Food and Drug Administration for a hospital SARS-CoV-2 test.

The rapid test is for hospital use on site to screen patients and healthcare workers and offers results in less than three hours from nasopharyngeal and oropharyngeal swabs. BioGX's test will run on the BD Max system, which processes 24 samples at once. 

BioGX developed the Sample-Ready ready-to-use assay for the BD Max system, and it is based on the same viral RNA targeting sequences and PCR detection as the assay from the US Centers for Disease Control and Prevention, which received EUA in February.

The fully automated BD Max platform, which can process 24 samples simultaneously, is installed in "hundreds" of laboratories in almost every state in the US, the two companies said, and the new test will add capacity for 50,000 tests per week across the country.

BD and BioGX submitted the test to FDA in mid-March for EUA.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.